Development of bispecific antibody for targeted therapeutic delivery with improved penetration and brain retention in alzheimer's disease
Active Grant Awarded
- Award ID
- FAG102000U4BBM8
- Recipient
-
West Virginia University Research Corporation UEI M7PNRH24BBM8
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $55,114
Award facts
- Assistance listing
- 93.AG4 National Institute on Aging Training Individual Projects
- Completion date 1% complete
- Place of performance
- Everettville, WV 26505, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease is a progressive neurodegenerative disorder affecting millions worldwide, with no curative therapies. A significant barrier to effective treatment is poor drug penetration across the blood-brain barrier (BBB) and insufficient retention of therapeutics in the brain. Existing approaches, including monoclonal antibody therapies targeting amyloid-beta, suffer from poor BBB penetration and rapid clearance. While receptor- mediated transcytosis strategies have shown potential, their clinical translation has been hindered by species- specific differences in receptor expression, off-target effects, and inadequate brain retention. These challenges highlight the need for novel central nervous system (CNS) drug delivery strategies that enable both effective BBB penetration and prolonged retention in brain tissue. The objective of this study is to construct and validate a bispecific antibody-drug carrier conjugate system that improves therapeutic brain delivery by integrating two variable lymphocyte receptor (VLR) targeting arms: (1) one to mediate BBB transport, and (2) one targeting neuronal structures to support sustained brain retention. This dual-targeting design aims to enhance brain uptake while minimizing clearance, addressing key limitations in CNS drug delivery. Aim 1 will employ yeast surface display screening of a VLR library to enable the unbiased identification of novel neuronal-binding VLR candidates. Top candidates will undergo elisa-based affinity assessment and neuronal specificity validation in 3D human induced pluripotent stem cell (IPSC)-derived brain assembloids, a physiologically relevant preclinical model. Aim 2 will construct and evaluate the bispecific antibody-drug carrier conjugate. The system will be evaluated in an in vitro BBB transwell model with 3D human IPSC-derived brain assembloids to assess BBB penetration, neuronal retention, and therapeutic delivery. In vivo proof-of-concept studies in C57BL/6 mice will preliminarily assess BBB penetration and brain uptake. This work is impactful because IT directly addresses the dual challenges of BBB penetration and brain retention by integrating bispecific antibody engineering with unbiased ligand discovery and physiologically relevant models. The findings of this study will contribute to the long-term goal of improving therapeutic brain delivery and retention for the treatment of alzheimer's disease and other CNS disorders. The proposed training plan spans antibody library screening, in vitro models, liposome formulation and functionalization, transwell BBB models, and murine models. Training will be conducted at west virginia university, including the rockefeller neuroscience institute, a collaborative and well-resourced environment with significant expertise in CNS drug delivery. The research will be guided by an interdisciplinary mentorship team, including sponsor DR. Moriah katt, an expert in BBB modeling and antibody engineering, and CO-sponsor DR. Peter konrad, a leader in translational neuroscience and neurosurgery. Experience gained in the proposed study will support my professional goals of becoming an independent physician scientist in the field of neuro-oncology.
Quick answers
Who received award FAG102000U4BBM8?
FAG102000U4BBM8 was awarded to West Virginia University Research Corporation by National Institute on Aging (National Institutes of Health) on November 16, 2026.
How much is award FAG102000U4BBM8 worth?
$55,114 has been obligated on FAG102000U4BBM8.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award